-
Mashup Score: 7Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs - 6 month(s) ago
Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 0Tonsillectomy for the Treatment of Suspected Sleep Apnea with Subsequent Improvement of Chronic Migraine - Practical Neurology - 11 month(s) ago
Tonsillectomy is a well-tolerated surgical procedure that can improve obstructive sleep apnea and possibly the frequency and intensity of comorbid migraine.
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 47 Common Myths About Migraine | American Migraine Foundation - 1 year(s) ago
Check out some of the common migraine myths to help you sort fact from fiction and get to migraine management plan that works for you.
Source: American Migraine FoundationCategories: Latest Headlines, Pain ManagementTweet-
No matter where you are in your migraine journey, it’s important to remember that there is always more to learn about migraine–especially when it comes to myths in the community. Read our blog for a full breakdown on seven myths about #migrainetreatment: https://t.co/3JQfE3ukNw https://t.co/pE5vkIFpbc
-
-
Mashup Score: 2
Five alternative treatment options for migraine, including magnesium, green light therapy and biofeedback.
Source: American Migraine FoundationCategories: Latest Headlines, Pain ManagementTweet
-
Mashup Score: 0Migraine Treatment Guidelines - 2 year(s) ago
Migraine Challenge Center FULL MENU Close Menu …
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 3American Academy of Neurology :: Catalog - 3 year(s) ago
NewNeuroBytes: Aducanumab for Alzheimer’s DiseaseQuestions about the NeuroBytes Program?Email OnlineLearningCenter@aan.com. Or Contact Member Services:Email MemberServices@aan.com. Call (800) 879-1960 or (612) 928-6000 (International).View DetailsBuy NowNewNeuroBytes: CGRP in the Treatment and Prevention of MigraineQuestions about the NeuroBytes Program?Email OnlineLearningCenter@aan.com. Or…
Source: learning.aan.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 3Advanced Practice Practitioners and Migraine | AMF - 3 year(s) ago
Read how advanced practice practioners like nurse practitioners and physician assistants can help you better manage migraine with expanded access to care, education and support.
Source: American Migraine FoundationCategories: Latest Headlines, Pain ManagementTweet
-
Mashup Score: 0FDA approves DHE-based migraine treatment Trudhesa - 3 year(s) ago
The FDA approved dihydroergotamine mesylate for the treatment of adults with acute migraine with or without aura, according to a press release from the drug’s manufacturer. Dihydroergotamine mesylate (Trudhesa, Impel NeuroPharma) is a nasal spray that, via a Precision Olfactory Delivery system, provides 0.725 mg of the medication with each spray.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3Outcomes in clinical trials for migraine: What should we measure and who should decide? - 3 year(s) ago
Click on the article title to read more.
Source: American Headache SocietyCategories: Latest Headlines, Pain ManagementTweet
-
Mashup Score: 6
The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers including neurologists, primary care physicians and advanced practice providers.
Source: American Headache SocietyCategories: Latest Headlines, Pain ManagementTweet
The evolving migraine treatment landscape includes FDA-approved drugs like Aimovig, Emgality, and Nurtec, along with the innovative nasal spray Zavzpret, providing effective options for both acute and preventative treatment. #MigraineTreatment Read More: https://t.co/vGbefVfv35